GlassScriptPhysician profile
Peter J Dourdoufis
NPI 1528042553
$20,564.26
in general payments reported to CMS, 2019-2025
25 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,946 · 2021: $2,331 · 2022: $103 · 2023: $667 · 2024: $571 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $10,396.58 | 2019-2021 | |
| Boston Scientific Corporation | $3,203.11 | 2019-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $2,764.11 | 2019-2023 | |
| Abbott Laboratories | $779.36 | 2019-2025 | Aveir, Optis, Dragonfly Opstar |
| Janssen Pharmaceuticals, INC | $588.46 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $584.67 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $365.81 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $272.11 | 2025 | Amvuttra |
| Amgen INC. | $221.62 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.90 | 2019-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $166.00 | 2019 | |
| Lantheus Medical Imaging, INC. | $158.35 | 2020-2025 | Definity |
| Astrazeneca Pharmaceuticals LP | $145.47 | 2019-2022 | |
| Pfizer INC. | $112.67 | 2019-2025 | |
| Novo Nordisk INC | $110.43 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $106.52 | 2021 | |
| Cardiovascular Systems INC. | $84.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2019 | |
| Medtronic, INC. | $62.10 | 2021-2024 | Linq II, Onyx Frontier |
| Regeneron Healthcare Solutions, INC. | $49.63 | 2019 | |
| Allergan, INC. | $37.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.95 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.10 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $25.13 | 2020 | |
| Smith+Nephew, INC. | $17.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dourdoufis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.